DICE Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q3 2020 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
DICE Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2020 to Q2 2023.
  • DICE Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2023 was -$39.5M, a 81.6% decline year-over-year.
  • DICE Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2023 was -$119M, a 62.7% decline year-over-year.
  • DICE Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$88.2M, a 85.3% decline from 2021.
  • DICE Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$47.6M, a 101% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 -$119M -$39.5M -$17.8M -81.6% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-08
Q1 2023 -$101M -$31.6M -$12.7M -67.4% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-11
Q4 2022 -$88.2M -$26.5M -$10.2M -63.2% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-15
Q3 2022 -$78M -$21.2M -$5.04M -31.2% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-09
Q2 2022 -$72.9M -$21.7M -$14.6M -203% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$58.4M -$18.9M -$10.8M -133% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$47.6M -$16.2M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-15
Q3 2021 -$16.1M -$10.2M -170% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$7.17M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$8.09M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q3 2020 -$5.98M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.